Gaithersburg, Maryland, USA
We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for miRecule on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
